Abstract
During the last few years, adoptive cellular therapy (ACT) — the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration — has been tested for treatment of melanoma tumours. Initial ACT used melanoma -infiltrating lymphocytes (TIL) that often contain tumour reactive lymphocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Keywords: lymphocyte, TCR transgenic T cells, melanoma infiltrating lymphocytes, tumour antigen, Peripheral Blood Mononuclear Cell
Current Cancer Therapy Reviews
Title: Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma
Volume: 4 Issue: 2
Author(s): Nathalie Labarriere, Brigitte Dreno and Francine Jotereau
Affiliation:
Keywords: lymphocyte, TCR transgenic T cells, melanoma infiltrating lymphocytes, tumour antigen, Peripheral Blood Mononuclear Cell
Abstract: During the last few years, adoptive cellular therapy (ACT) — the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration — has been tested for treatment of melanoma tumours. Initial ACT used melanoma -infiltrating lymphocytes (TIL) that often contain tumour reactive lymphocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Export Options
About this article
Cite this article as:
Labarriere Nathalie, Dreno Brigitte and Jotereau Francine, Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310142
DOI https://dx.doi.org/10.2174/157339408784310142 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Polycationic Nanoparticles as Nonviral Vectors Employed for Gene Therapy in vivo
Mini-Reviews in Medicinal Chemistry Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Applications of Triazolopyrimidine-Based Bioactive Compounds in Medicinal and Agrochemical Chemistry
Mini-Reviews in Medicinal Chemistry Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry In Vitro Inhibition Effect and Molecular Docking Study of Curcumin, Resveratrol, and Quercetin on Human Erythrocyte Glutathione Transferase
Current Enzyme Inhibition Monitoring Molecular, Functional and Morphologic Aspects of Bone Metastases Using Non-Invasive Imaging
Current Pharmaceutical Biotechnology Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets The Role of Essential Oils and the Biological Detoxification in the Prevention of Aflatoxin Borne Diseases
Current Topics in Medicinal Chemistry Derivatives of Resveratrol: Potential Agents in Prevention and Treatment of Cardiovascular Disease
Current Medicinal Chemistry FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Current Pharmaceutical Design Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery